Abstract
Breast cancer is well known for its significant heterogeneity, and numerous studies have focused primarily on intertumor heterogeneity. However, increasing evidence highlights the critical role of intratumor heterogeneity (ITH), a complex phenomenon driven by multiple factors in breast cancer progression and treatment. Some studies have demonstrated that higher levels of ITH in breast cancer patients are associated with poor prognosis, but addressing this phenomenon holds potential benefits. In this review, we discuss the origins of ITH, including clonal evolution and cancer stem cell (CSC) models, and the influence of external factors such as the tumor microenvironment and metabolic reprogramming. We also summarize current methods for assessing ITH and potential therapeutic approaches. Understanding ITH can improve diagnostic accuracy and provide a basis for personalized treatment strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
